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Abstract 
Background: Androgen insensitivity syndrome (AIS), a disorder of sexual development in 46, XY individuals, is 
caused by loss-of-function mutations in the androgen receptor (AR) gene. A variety of tumors have been reported in 
association with AIS, but no cases with colorectal cancer (CRC) have been described.
Case presentation: Here, we present a male patient with AIS who developed multiple early-onset CRCs and his 
pedigree. His first cousin was diagnosed with AIS and harbored the same AR gene mutation, but with no signs of CRC. 
The difference in clinical management for the two patients was that testosterone treatment was given to the proband 
for a much longer time compared with the cousin. The CRC family history was negative, and no germline mutations in 
well-known CRC-related genes were identified. A single nucleotide polymorphism array revealed a microduplication 
on chromosome 22q11.22 that encompassed a microRNA potentially related to CRC pathogenesis. In the proband, 
whole exome sequencing identified a polymorphism in an oncogene and 13 rare loss-of-function variants, of which 
two were in CRC-related genes and four were in genes associated with other human cancers.
Conclusions: By pathway analysis, all inherited germline genetic events were connected in a unique network 
whose alteration in the proband, together with continuous testosterone stimulation, may have played a role in CRC 
pathogenesis.
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Background
Tissue resistance to androgens (i.e., testosterone and 
its 5α-reduced product dihydrotestosterone) leads to 
androgen insensitivity syndrome (AIS). AIS is the most 
well-known specific cause of the 46,XY disorder of sex 
development (DSD), but estimates of its prevalence vary 
widely, depending on the molecular assessment method 
used for diagnosis [1–3]. Pathogenesis of this disorder is 
essentially the result of mutations in the androgen recep-
tor (AR) gene, but as clearly stated by Gottlieb et al. [4], 
“… solely identifying the genotype of an AIS individual 
may no longer be sufficient to draw conclusions about 
the effect of an AR mutation on the persons’ pheno-
type…”. The AR gene, located on chromosome Xq11–q12, 
contains eight exons and seven introns spanning ~90 kb 
of DNA. It encodes for the androgen receptor, which is 
a transcription factor and a member of the steroid hor-
mone receptor family within the nuclear receptor super-
family [2]. AR is the only gene linked with AIS. More 
than 500 different AR mutations, distributed throughout 
the gene sequence, have been reported [3]. Furthermore, 
there is variable phenotypic expression related to spe-
cific mutations, with identical mutations linked to dif-
ferent phenotypes [3]. The clinical manifestations of AIS 
vary from the complete form (CAIS), where testosterone 
has no effect on sexual development and the genitals 
are entirely female, to milder degrees of underviriliza-
tion (the partial form; PAIS) or the mild form (MAIS) in 
which males have gynecomastia and/or infertility. The 
lifetime risk of development of neoplasms in patients 
with AIS, even though not defined accurately due to the 
small size of the analyzed series, was reported to be 0.8% 
for CAIS and 5.5%–15% for PAIS, with tumors originat-
ing from testicular germ cells, testicular stromal cells, or 
other mesenchymal cells [5–8].
To date, no cases of AIS with a documented history 
of colorectal cancer (CRC) have been described. In this 
paper, we describe the clinical and molecular analyses of a 
proband affected by PAIS who developed multiple CRCs. 
The patient presented with primary CRC at an early age 
(27 years). With the aim of identifying the constitutional 
genetic events that could have played a role in the early 
onset of CRC in the proband, we used a combination of 
two advanced high-throughput technologies: (i) high-
resolution single nucleotide polymorphism (SNP) array 
analysis to investigate copy number variation (CNV) and 
uniparental disomy (UPD) events and (ii) whole exome 
sequencing (WES) analysis to investigate single nucleo-
tide variants (SNVs) and small insertions and deletions 
(INDELs). A set of inherited germline genetic variations 
that may be responsible for CRC pathogenesis were iden-
tified in this patient.
Case report
Herein, we report a 46,XY male patient (III.2 of the fam-
ily presents in Fig. 1) who, at birth (1983), presented with 
undescended testes, severe hypospadias, and a micrope-
nis and who received a clinical and molecular diagnosis 
of PAIS. At 6  months of age, adrenal hormone dosage 
results were normal, which excluded adrenal disease. 
Testosterone enanthate (250  mg every 2  weeks through 
intramuscular injection) was provided regularly from 
age 3 to 27  years. At 10  years of age, adrenocortico-
tropic hormone and beta human chorionic gonadotro-
pin tests excluded a deficit in 5α-reductase. At 13 years 
of age, gynecomastia was recorded. The proband devel-
oped CRC at 27  years old and underwent a left hemi-
colectomy; at postoperative pathologic examination, the 
tumor was diagnosed as a G2, stage pT1N0 rectosigmoid 
adenocarcinoma. When he was 30 years old, a metachro-
nous CRC was diagnosed and treated with segmental 
resection; at postoperative pathologic examination, the 
tumor was diagnosed as a G2, stage pT3N0 adenocarci-
noma. The tumor relapsed locally 4 months later and was 
treated with radiotherapy, chemotherapy (capecitabine), 
and surgical proctectomy. At present, the disease is in 
progression.
The family history of CRC was negative. The proband 
was tested for germline mutations in the genes respon-
sible for major CRC syndromes using Sanger sequenc-
ing [9–11], but no pathogenic mutations were identified 
(Additional file 1: Table S1). Immunohistochemical char-
acterization of mismatch repair proteins as well as micro-
satellite instability analysis were performed as reported 
[12–14] on the primary CRC tissue. The normal staining 
pattern for all proteins is nuclear, and a case is consid-
ered positive only in the presence of nuclear staining of 
neoplastic cells. A case is considered defective for the 
expression of one protein only when there is a complete 
absence of nuclear staining of neoplastic cells in the pres-
ence of an unquestionable internal positive control rep-
resented by normal epithelial cells, stromal cells, muscle 
cells, or lymphocytes. The proband’s CRC tissue revealed 
no alterations in mismatch repair proteins.
The proband’s cousin (III.3) was also diagnosed with 
PAIS. He underwent gynecomastia, hypospadia, and 
cryptorchidism corrective surgeries, and testosterone 
enanthate (250 mg every 2 weeks through intramuscular 
injection) was provided in an irregular regimen from age 
15 to 20 years. At present, the cousin is healthy.
Molecular analysis of the AR gene through Sanger 
sequencing [15] of DNA from both III.2 and III.3 
revealed a missense mutation in AR exon 7 (NM_000044: 
c.G2522A; NP_000035.2: p.R841H). By segregation anal-
ysis, the AR mutation was found to be inherited from 
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their healthy mothers (II.2, II.3), who were born from 
consanguineous parents. Furthermore, this variant was 
present in the DNA of the proband’s sister (III.1).
Molecular analyses
Genomic DNA was extracted from whole blood speci-
mens of the proband and his relatives using a QIAamp 
DNA Blood Maxi Kit (Qiagen, Hilden, Germany) and 
from secondary CRC and matched normal colon tis-
sue of the proband using a QIAamp DNA mini Kit 
(Qiagen). Genomic DNA from whole blood samples 
from family subjects (II.1, II.2, II.3, III.2, and III.3) and 
from CRC tissue of the proband was subjected to high-
resolution genome-wide SNP array analysis using a 
Cytoscan HD array (Affymetrix, Inc., Santa Clara, CA, 
USA) and WES using the SOLiD 5500xl WF platform 
(Life Technologies, Gaithersburg, MD, USA). WES 
was also performed on genomic DNA isolated from 
the normal colon mucosa of the proband. Two predic-
tive tools, i.e., sorting intolerant from tolerant (SIFT) 
[16] and polymorphism phenotyping version 2 (Poly-
Phen-2) [17], were used to predict the effect of cod-
ing non-synonymous variants on protein function. To 
ensure the selection of genes associated with the cur-
rently best-characterized hereditary CRC syndromes, 
a review of the CRC panel-based clinical genetic tests 
listed in the GeneTest database was performed using 
“colorectal cancer” and “colon cancer” as key words. The 
final list of genes was then used to query in the PubMed 
and Online Mendelian Inheritance in Man (OMIM) 
databases to verify the association between the genes 
and a CRC predisposition. Genes that were found to 
be significantly somatically mutated in CRC patients 
and reported in the TumorPortal website (http://www.
tumorportal.org) were included. A final list of 57 genes 
was used for analysis of the WES data (Additional file 2: 
Table S2; Additional file 3: Tables S3).
A network investigation of the identified mutated genes 
and genes harbored in the aberrant chromosomal regions 
was performed using Ingenuity® Pathway Analysis (IPA®, 
QIAGEN Redwood City, http://www.qiagen.com/inge-
nuity; Version 23814503—23 March 2015).
Identification of genetic events involved in PAIS
To identify the potential involvement of further genomic 
imbalances in the etiology of PAIS, we first evaluated 
the CNVs identified in the two affected cousins. Shared 
chromosomal regions identified as being deleted or 
duplicated in both cousins were carefully evaluated to 
verify their potential role in the pathogenesis of AIS. This 
analysis did not reveal the presence of CNVs that might 
have a role in the manifestation of the PAIS phenotype. 
Fig. 1 Pedigree of the family. Squares indicate males, and circles represent females. Slashed symbols indicate deceased individuals. Unfilled symbols 
indicate unaffected individuals. Black dotted circles indicate unaffected individuals carrying the androgen receptor (AR) gene mutation. Half-black 
shaded symbols represent individuals carrying the AR gene mutation who are affected by partial androgen insensitivity syndrome (PAIS). The blue 
arrow indicates the proband. The half-blue shaded symbol indicates that the proband presented with colorectal cancer (CRC). y.o. indicates the age 
at the time of the analysis. The proband developed primary CRC at 27 years old, metachronous CRC at 30 years old, and recurrent CRC at 31 years 
old
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Then, we scanned the exome data of the affected cous-
ins using a list of 37 genes known to be responsible for 
DSD (Additional file 4: Table S4). This analysis confirmed 
the presence of the missense c.2522G > A mutation of the 
AR gene and excluded the occurrence of other causative 
genetic events being responsible for PAIS in both cousins 
(Additional file 5: Table S5).
Identification of CNVs involved in the early onset of CRC
High-density SNP array (blood) analysis of the proband 
and his relatives was performed to investigate CNVs and 
UPD. Overall, in the proband, we identified 14 CNVs 
(Table  1; Additional file  6: Table S6): 4 (two losses and 
two gains) in gene desert chromosomal regions and 10 
(two losses and eight gains) in chromosomal regions 
involving genes. All identified CNVs were also detected 
in the SNP array data of the CRC tissue. By comparison 
with the Database of Genomic Variants, 10 of the identi-
fied CNVs were found, with a frequency of <1% in healthy 
human control individuals from worldwide populations. 
Among the CNVs, four involved cancer-related genes, 
and one was a microRNA gene. Specifically, the identified 
copy number gains in the chromosomal regions 1p36.22, 
involving the PRY domain-containing SOCS box protein 
1 (SPSB1) gene; 14q32.33, involving the immunoglobu-
lin heavy constant gamma 1 (IGHG1) gene; Xp221.33 or 
Yp11.32, encompassing the cytokine receptor-like fac-
tor 2 (CRLF2) gene; and the copy number loss of chro-
mosomal region 10q21.3, involving the intronic region 
of the catenin α 3 (CTNNA3) gene, have been previously 
identified in human cancers other than colon cancer. A 
microduplication of chromosome 22q11.22, encompass-
ing MIR650 gene, previously related to CRC, was also 
detected.
No UPD events spanning whole chromosomes or chro-
mosomal segments were detected in the proband. The 
segregation analysis of the 14 CNVs revealed that only 
one was de novo, whereas four were identified in both 
parents, three were inherited paternally, and five were 
inherited maternally.
Identification of gene alterations involved in the early 
onset of CRC
WES generated an average of 456 × 106 reads per sample, 
mapped to the reference genome with an average of 64.6% 
at a mean depth of 179-fold exon coverage (Table  2). 
The average depth coverage above 150, obtained for the 
proband, father, and cousin, far exceeded the normal 
standards applied for the identification of germline vari-
ants, making the results very robust. Furthermore, in the 
proband, the germline variants were cross validated in 
different tissues. Finally, the genotype of each proband 
variant could be further confirmed from the exome data 
of his parents.
To identify variants associated with CRC in the 
proband, we carried out WES on DNA from blood and 
normal colon mucosa samples, and the variants shared 
between the two sources were analyzed using a candidate 
gene approach and a whole-exome approach (Fig. 2). The 
final set of prioritized variants was evaluated using the 
exome data from the relatives of the proband.
Candidate gene approach
By searching variants in the 57 prior candidate CRC-
related genes without filtering criteria, we identified 
27 variants present in the normal genomic DNA of the 
proband. After visually examining the variants using 
Integrative Genomic Viewer (IGV) software, one vari-
ant was excluded, thus reducing the final list to 26 var-
iants (13 heterozygous and 13 homozygous) harbored 
in 17 CRC-related genes (Table  3; Additional file  6: 
Table S6).
Analysis using the 1000 genomes database revealed 
that 24 of the 26 variants had a minor allele frequency 
(MAF)  >5%, indicating that these SNVs could be con-
sidered common variants, whereas the remaining two 
identified in the polymerase (DNA directed), epsilon, 
catalytic subunit (POLE) (chr12:133233977G  >  A, syn-
onymous mutation) and protein tyrosine phosphatase, 
receptor type, J (PTPRJ) (rs11382316, intronic mutation) 
genes represented rare variants.
We focused our analysis on variants that produced 
an altered protein product and found that five of the 26 
variants were non-synonymous. Among these, only the 
rs1058808 polymorphism of the erb-b2 receptor tyrosine 
kinase 2 (ERBB2) gene was predicted to be deleterious by 
both SIFT (damaging, tolerance index score ≤0.05, low 
confidence prediction) and PolyPhen-2 (possibly dam-
aging, tolerance index score in the 0.453–0.956 range) 
(Additional file 7: Table S7).
A search for the identified variants in the MAF file 
reporting somatic variations of the 233 samples from the 
Cancer Genome Atlas (TCGA) project indicated that 
they were not described in the CRC data set. The Human 
Gene Mutation Database (HGMD) [18], Leiden Open 
Variation Database (LOVD) [19], and Human Genome 
Variation Society (HGVS) and ClinVar databases [20], 
which were used to assess the pathogenicity of these vari-
ants, indicated no evident pathogenicity associated with 
CRC.
The variants identified in the proband were then evalu-
ated in the WES data of his relatives. Among the 13 het-
erozygous variants, six were inherited paternally, two 
were inherited maternally, and three were present in both 
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Table 2 Metrics of whole-exome sequencing (WES) analysis of the specimens from the proband and his relatives entering 
into the present study















Total reads 801,798,464 631,026,099 631,377,353 633,336,574 98,744,957 98,744,957 397,006,863
Mapped reads 481,096,544 350,445,297 434,605,056 330,283,413 66,488,953 73,450,351 243,481,688
On-target reads 266,671,188 185,116,968 217,278,894 237,886,825 47,482,595 65,141,598 142,790,642
% mapped reads 60.0 55.5 68.8 52.2 26.8 74.4 61.3
% on-target reads 55.4 52.8 50.0 72.0 71.4 88.7 58.7
% covered target 
reads
96.7 92.6 91.6 94.9 86.7 88.6 94.9
Average depth 
coverage


















27 variants 18 truncating variants
Variant selection
from 57 CRC 
susceptibility genes 397 exonic variants 






Fig. 2 Analysis of the workflow applied to prioritize variants found in the whole-exome sequencing (WES) data from the proband. Two differ-
ent sources of the proband’s DNA (blood and normal colon tissues) were analyzed with WES. A quality filter was first applied to minimize false 
positive variants, permitting us to obtain 19,673 and 18,696 variants in DNA in the blood and normal colon tissues from the proband, respectively. 
Since massively parallel sequencing can generate artifacts, a total of 11,737 variants shared between the two sources of DNA were used to apply 
a twofold strategy to identify variants associated with CRC. The first approach (“candidate gene approach”) selected 26 variants from the 57 CRC 
susceptibility genes; the second approach (“whole-exome approach”) selected 13 truncating variants with a minor allele frequency (MAF) <0.01. IGV 
the Integrative Genomic Viewer software
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parents; for the remaining two variants, due to low cover-
age of the targeted analyzed regions, the inheritance was 
not assessable. Among the 13 homozygous variants, eight 
were inherited from both parents. Two of the homozy-
gous variants included one allele that was transmitted 
from the father, while presumably the SNV harbored 
in the other allele occurred de novo. The inheritance of 
three of the homozygous variants was not assessable. 
A majority of the identified variants (22 of 26) was also 
detected in the proband’s cousin.
Whole‑exome approach
We focused our search on variants functionally anno-
tated and predicted to truncate the protein products, 
i.e., frameshift insertions and deletions and non-sense 
mutations. Variants were excluded if they were present 
in the 1000 Genomes Project and dbSNP138 databases 
at only MAF >0.01. Among 11,737 variants shared by the 
two sources of normal DNA of the proband, 18 truncat-
ing variants were identified, but the manual revision of 
these through IGV software subsequently excluded five 
of them. The remaining 13 variants were in a heterozy-
gous state (Table 4) and were essentially confirmed by the 
WES data of the proband’s relatives, i.e., four SNVs were 
inherited maternally and three were inherited paternally, 
whereas the presence of the other three in the aunt and 
cousin suggested possible inheritance from the proband’s 
mother. One rare variant in the HYDIN gene was identi-
fied in a heterozygous state in all members of the family.
Network and pathway analysis
To test putative enrichment for canonical pathways, dis-
ease, biological functions, and molecular networks, the 
genes residing in CNVs and those harboring truncating 
mutations were analyzed using QIAGEN’s Ingenuity® 
Pathway Analysis.
Significant gene association was observed only when 
the gene list was reduced to AR (mutated and causa-
tive of PAIS in the proband), MIR650 (already related 
to CRC pathogenesis and present in a rearranged chro-
mosomal region), ERBB2 (determined to be function-
ally impaired by the candidate gene approach), and the 
13 genes harboring truncating variants (identified by 
the whole-exome approach). In fact, 14 (87.5%) of these 
16 genes were found to be connected to each other in a 
unique relevant network called “Gene expression, cellular 
growth and proliferation, tissue development” (IPA score 
46) (Fig. 3). When a testosterone metabolite (dihydrotes-
tosterone) was added to the network, indirect interac-
tions with genes of the network, including ERBB2, were 
found in addition to the expected direct interaction with 
AR. Table  5 summarizes the main characteristics of the 
altered genes related to this network and their genetic 
association with the analyzed samples.
Discussion
This study provided a deep genomic analysis using 
SNP array and WES data of the constitutive DNA of a 
patient harboring the missense c.2225G > A (p.R841H or 
rs9332969) mutation of the AR gene. It has been reported 
that the R841H protein variation influences its binding 
to and interactions with androgens [21]; however, this 
substitution does not result in complete AR functional 
disruption [22] and gives rise to variable expression of 
the AIS phenotype [2, 23], suggesting that alterations in 
other genes may modulate and affect the final phenotype. 
Our SNP array and WES analysis of both affected cous-
ins in this study did not reveal the presence of additional 
causative genetic events responsible for the PAIS pheno-
type, thus strongly supporting the pathogenic role of the 
p.R841H variant in PAIS.
Our proband patient developed multiple CRCs at an 
early age, suggesting a hallmark of inherited cancer sus-
ceptibility along with familial aggregation [24, 25]. More-
over, it has been recently reported that genetic instability 
could explain the early onset of CRC [18]. Germline alter-
ations in the major CRC-associated genes adenomatous 
polyposis coli (APC), mutY homolog (MUTYH), mutL 
homolog 1 (MLH1), mutS homolog 2 (MSH2), and mutS 
homolog 6 (MSH6) were previously excluded. In this 
study, we employed two advanced high-throughput tech-
nologies, namely SNP array and WES, to investigate the 
involvement of other genetic susceptibility mechanisms 
responsible for early onset of CRC.
Among the 14 CNVs identified by the SNP array, four 
involved genes (SPSB1, CTNNA3, IGHG1, and CRFL2) 
have been implicated in tumorigenesis, however, other 
than in colon cancer, thus only one rearrangement, a 
duplication of the chromosomal region 22q11.22, may be 
of interest and relevant to this study. The amplified chro-
mosomal region included MIR650, which has among its 
targets the promoter region of the NDRG family mem-
ber 2 (NDRG2) tumor suppressor gene where it has been 
reported to be able to repress NDRG2 gene expression at 
the transcriptional level in CRC [26].
Among the 26 variants identified by WES following the 
candidate gene approach, a literature search revealed that 
the APC, caspase 8, apoptosis-related cysteine peptidase 
(CASP8), ERBB2, MLH1, and PTPRJ gene variants have 
been previously investigated to verify their roles in cancer 
predisposition (see all the references in Additional file 7: 
Table S7). Even if no clear pathogenic mutations respon-
sible for CRC insurgence were identified, it is worth not-
ing that rs1058808 in the ERBB2 gene, present in the 
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heterozygous state, is harbored in the regulatory C-termi-
nal domain of the ErbB2 protein. This protein represents 
a hub of the protein–protein interaction network associ-
ated with the ErbB2 receptor, which plays a crucial role in 
signaling cascades regulating cell growth, differentiation, 
and migration [27]. Furthermore, previous studies investi-
gating the role of the rs1058808 polymorphism have sug-
gested that it may represent a functional polymorphism 
inducing the overexpression of the ErbB2 protein [28, 29]. 
At present, in a series of 104 sporadic CRC patients, three 
mutations in the ERBB2 kinase domain have been found 
[30]; however, the mutation identified in the proband 
patient was located in a different region. Finally, our WES 
approach identified 13 genes harboring loss-of-function 
variants in the heterozygous state in the proband.
The analysis of the prioritized genes harboring the loss-
of-function variants combined with the ERBB2, AR, and 
MIR650 genes through IPA software revealed that 14 of 
the 16 genes were connected in a unique network, called 
the “Gene expression, cellular growth and proliferation, 
tissue development” network. The core molecular hub in 
this network is represented by seven genes (MIR650, alco-
hol dehydrogenase, iron containing 1 [ADHFE1], charged 
multivesicular body protein 2A [CHMP2B], DENN 
domain containing 2D [DENND2D], kalirin RhoGEF 
kinase [KALRN], meprin A subunit alpha [MEP1A], and 
transglutaminase 4 [TGM4]) connected with AR and 
ERBB2, revealing an altered cross-talk between these two 
signaling pathways. From the literature, four of these six 
genes (CHMP2B, DENND2D, KALRN, and TGM4) have 
been previously identified as being involved in oncogen-
esis, while 3 (MIR650, ADHFE1, and MEP1A) may be 
related to CRC development and differentiation (see all 
the references in Additional file 8: Table S8). Considering 
Fig. 3 Network of genes and molecules inferred from Ingenuity® Pathway Analysis (IPA). The 13 genes exhibiting truncating variants were 
combined with the erb-b2 receptor tyrosine kinase 2 (ERBB2) gene harboring the rs1058808 single nucleotide polymorphism (SNP), which was 
predicted to be deleterious by the sorting intolerant from tolerant (SIFT) and polymorphism phenotyping version 2 (PolyPhen-2) tools, the micro-
RNA-650 (MIR650) gene (a colorectal cancer-related gene), and the androgen receptor (AR) gene harboring the pathogenic rs9332969 SNP to test 
the putative enrichment of the canonical pathways, disease and biological functions, and molecular networks. When the short list of altered genes 
was examined using the IPA software, a single pathway (top functions: gene expression, cellular growth and proliferation, tissue development) with 
a high score (46, P < 0.001) was identified. Genes highlighted in blue were identified to be altered in III.2 (proband) and III.3 (cousin). Genes high-
lighted in red were found to be altered only in subject III.2. The dihydrotestosterone molecule is highlighted in green
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the genes connected in the network but that were not 
altered in sequence, the presence of the interleukin-6 (IL-
6) gene and its relation to MEP1A are also noteworthy. 
Indeed, IL-6 has been shown to be increased in Meprin 
KO mice [31], and IL-6 has been found to be up-regu-
lated in colon cancer tissues and significantly associated 
with an increased risk of relapse [32]. Moreover, it should 
be noted that, among these 14 connected genes, five 
were not altered in the cousin. Testosterone, indirectly 
connected with TGM4 and ERBB2, was provided con-
tinuously for 24  years to the proband, including devel-
opmental years, whereas only 5  years of discontinuous 
treatment was provided to the cousin after age 15 years.
In physiologic conditions and in the presence of an 
active AR, the activity of testosterone and dihydrotes-
tosterone hormones can be modulated by (i) a classic 
genomic model mediated by the cytosolic AR protein 
and (ii) a non-genomic model mediated by the func-
tional membrane AR [33]. Since membrane AR activa-
tion via testosterone induces cytosolic signaling cascades 
involving molecules belonging to the ERBB2 pathway, 
it is tempting to hypothesize the possible existence of 
cross-talk between testosterone, membrane AR, and 
ErbB2 protein [34–38]. Considering the role of testos-
terone in CRC development, the literature indicates 
that the risk of CRC shows sexual dimorphism, with a 
higher incidence and earlier onset in men [39]. Whether 
this disparity depends on protective factors in women, 
tumor-promoting factors in males, or both, is unknown. 
A recent epidemiologic study indicated that, in men with 
functional AR protein, higher levels of testosterone and 
sex hormone-binding globulin were associated with a 
decreased risk for developing CRC, but lower andro-
genicity may increase the risk of developing CRC in 
males [40, 41]. A tumor-promoting effect of testosterone, 
likely not dependent on AR activity, has been reported 
via the elegant use of the APCPirc/+ (Pirc) rat model, sug-
gesting that sex disparity in the development of colonic 
adenomas depends directly on the effect of testosterone, 
rather than on a protective effect of female hormones 
[42]. Testosterone has been shown to stimulate the 
growth of lung and colon cancer cells in vitro, a mecha-
nism that can be halted with anti-androgens [43, 44]. A 
population-based study that aimed to verify the asso-
ciation between plasma testosterone and overall cancer 
risk revealed that increased levels of plasma testosterone 
were associated with an increased risk of early death after 
cancer, but not with risk of cancer incidence [45]. Put-
ting all these factors together, these observations suggest 
a potential effect of testosterone on cancer development 
and prognosis.
Thus, we speculate that testosterone treatment may 
have played a role in the initiation of cancer in the colon 
tissue of the proband, probably exerting a direct inter-
action with the poorly or non-functional cytosolic AR 
protein or an indirect action through the membrane AR 
Table 5 Summary of  the characteristics of  genes connected in  the “Gene expression, cellular growth and  proliferation, 
tissue development” network
Gene symbol Gene name Exonic variant type Accession number Amino acid change Inheritance
PAIS
 AR Androgen receptor Missense NM_000044 p.R841H Mother
Candidate gene approach
 ERBB2 Erb-b2 receptor tyrosine kinase 2 Missense NM_001005862 p.P1140A Father/de novo
Whole-exome approach
 ADHFE1 Alcohol dehydrogenase, iron containing, 1 Stop gain NM_144650 p.R6X NV
 AHNAK2 AHNAK nucleoprotein 2 Stop gain NM_138420 p.W4640X NV
 BTN3A3 Butyrophilin, subfamily 3, member A3 Stop gain NM_006994 p.Trp171X NV
 CHMP2B Charged multivesicular body protein 2B Stop gain NM_014043 p.Arg22X Father
 DENND2D DENN/MADD domain containing 2D Stop gain NM_024901 p.Arg16X Mother
 HYDIN HYDIN, axonemal central pair apparatus protein Frameshift del NM_001270974 p.I3904fs Father/mother
 KALRN Kalirin, RhoGEF kinase Stop gain NM_007064 p.Arg10X Mother
 MEP1A Meprin A, alpha (PABA peptide hydrolase) Stop gain NM_005588 p.Q296X Mother
 SCCPDH Saccharopine dehydrogenase (putative) Frameshift ins NM_016002 p.V55fs NV
 TGM4 Transglutaminase 4 Stop gain NM_003241 p.W269X Father
 ZNF844 Zinc finger protein 844 Frameshift del NM_001136501 p.L346fs Mother
Gene content Chromosomal aberration Inheritance
SNP array
 MIR650, MIR5571, IGLL5 22q11.22 (23,004,886–23,258,369) × 3 Father/mother
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protein. This could have led to the activation of a cyto-
solic signaling cascade involving the ErbB2 protein, 
which may have a functional effect in the patient.
Conclusions
The etiology of CRC is complex and multifactorial, 
involving an interplay between multiple genetic and 
environmental factors. Our in-depth genetic analysis of 
the proband and his family supports the hypothesis that 
the identified genetic alterations, in a multi-hit model of 
the inheritance of common and rare variants in multiple 
genes, might have contributed to the early onset of CRC 
in combination with environmental factors, such as a 
potential iatrogenic effect due to a continuous high-dose 
treatment with testosterone during developmental years. 
To confirm the relevance of the identified network of 
genes and molecules in CRC predisposition, further AIS 
families and preclinical model systems should be ana-
lyzed. Moreover, these findings highlight the importance 
of these types of studies to develop a better understand-
ing of the molecular basis of a disease and, consequently, 
for better clinical management of patients.
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